Amundi Seagen Inc. Transaction History

Amundi

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $27.6 Million - $31.2 Million	144,147 Added 48.88%	439,037 $93.1 Million
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $3.83 Million - $4.21 Million	20,430 Added 7.44%	294,890 $56.8 Million
Q1 2023 May 15, 2023	SELL	$127.59 - $203.08 $10.6 Million - $16.9 Million	-83,235 Reduced 23.27%	274,460 $55.6 Million
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $15.5 Million - $18.4 Million	132,380 Added 58.75%	357,695 $46 Million
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $19.1 Million - $25.5 Million	141,317 Added 168.24%	225,315 $30.8 Million
Q2 2022 Aug 15, 2022	BUY	$108.81 - $179.33 $117,297 - $193,317	1,078 Added 1.3%	83,998 $14.8 Million
Q1 2022 May 16, 2022	SELL	$119.61 - $157.85 $1.21 Million - $1.6 Million	-10,144 Reduced 10.9%	82,920 $12.9 Million
Q4 2021 Feb 14, 2022	BUY	$142.57 - $190.86 $2.48 Million - $3.32 Million	17,419 Added 23.03%	93,064 $12.7 Million
Q3 2021 Nov 15, 2021	BUY	$142.45 - $169.82 $874,500 - $1.04 Million	6,139 Added 8.83%	75,645 $12.8 Million
Q2 2021 Aug 16, 2021	BUY	$135.08 - $161.1 $9.39 Million - $11.2 Million	69,506 New	69,506 $11 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

Stay updated on Amundi with notifications on news.